Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis.
Jean W LiewGregory C GardnerPublished in: The Journal of rheumatology (2019)
To our knowledge, this is the largest observational study of anakinra use in the inpatient setting for the acute treatment of crystal-associated arthritis. We observed a rapid response to anakinra, with 75% of episodes significantly improving or completely resolving within 4 days of the first dose. Our data also support the use of this biologic agent in individuals with infections, as well as perioperative individuals and immunosuppressed transplant recipients.
Keyphrases
- rheumatoid arthritis
- liver failure
- healthcare
- cardiac surgery
- patients undergoing
- palliative care
- respiratory failure
- electronic health record
- mental health
- big data
- drug induced
- intensive care unit
- solid state
- combination therapy
- machine learning
- hepatitis b virus
- extracorporeal membrane oxygenation
- smoking cessation